Free Trial
NASDAQ:INDP

Indaptus Therapeutics 3/13/2025 Earnings Report

Indaptus Therapeutics logo
$0.32 -0.01 (-1.88%)
Closing price 03:57 PM Eastern
Extended Trading
$0.37 +0.05 (+15.96%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Indaptus Therapeutics EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.41
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Indaptus Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Indaptus Therapeutics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Indaptus Therapeutics' next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules.

Conference Call Resources

Indaptus Therapeutics Earnings Headlines

“You all just got a lot richer”
Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.
Indaptus Therapeutics reports new data on Phase 1 trial of Decoy20
See More Indaptus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Indaptus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Indaptus Therapeutics and other key companies, straight to your email.

About Indaptus Therapeutics

Indaptus Therapeutics (NASDAQ:INDP), a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

View Indaptus Therapeutics Profile

More Earnings Resources from MarketBeat